Methamphetamine use disorder is one of the most serious substance use crises in the United States. Federal surveillance data, collected annually through national surveys, treatment admissions systems, and mortality registries, provide a detailed picture of the scope of the problem: who is affected, where, and with what consequences. Understanding these statistics is essential for clinicians, policymakers, public health professionals, and the families of people living with this condition.
This article presents current, verified statistics on methamphetamine use prevalence, use disorder rates, treatment admissions, overdose mortality, and demographic and regional trends. These numbers represent real people and real families. They are shared here to show the scale of the problem and why access to treatment matters.
Methamphetamine Use Prevalence: How Many Americans Are Affected
The most comprehensive annual source of data on drug use in the United States is the National Survey on Drug Use and Health (NSDUH), conducted by SAMHSA. The 2022 NSDUH, the most recently published full-year national report at the time of writing, found that approximately 2.7 million people aged 12 or older (1.0 percent of the U.S. population) reported using methamphetamine in the past year. This figure reflects a significant increase from 1.4 million in 2016. The scope of methamphetamine use has nearly doubled in less than a decade.
The 2024 NSDUH, the most current available, recorded 0.8 percent of people aged 12 or older reporting past-year methamphetamine use, with SAMHSA characterizing the trend from 2021 through 2024 as showing no statistically significant change. This signals that methamphetamine use has plateaued at historically elevated levels rather than declining. Among adults aged 26 or older, the rate was 1.0 percent in 2024, consistently the highest of any age group. Methamphetamine use disorder most heavily burdens working-age and older adults.
Use among adolescents (aged 12 to 17) remains comparatively low at 0.2 percent in 2024, but the consequences for young people who do use methamphetamine are particularly severe, given the ongoing development of the adolescent brain’s prefrontal cortex and dopamine systems. Per the 2022 NSDUH, young adults aged 18 to 25 had a past-year use rate of 0.5 percent.
Methamphetamine Use Disorder: From Use to Clinical Diagnosis
Not everyone who uses methamphetamine develops a use disorder, but the drug’s high addiction potential means that a substantial proportion do. The 2022 NSDUH found that approximately 1.6 million people aged 12 or older met criteria for methamphetamine use disorder in the past year. That represents roughly 59 percent of past-year methamphetamine users, a use-to-disorder conversion rate that is exceptionally high compared to most other substances.
Earlier NSDUH data published in a peer-reviewed analysis in PMC (Methamphetamine Use in the United States: Epidemiological Update) documented that the number of people with past-year methamphetamine use disorder more than doubled from approximately 684,000 in 2016 to 1,048,000 in 2019, with increases observed across multiple demographic groups including men and women, heterosexual and gay/bisexual populations, and multiple racial and ethnic groups. The trend lines since then have continued upward.
Among adults aged 26 and older who reported past-year methamphetamine use in 2022, NIDA noted that nearly two out of three met criteria for a stimulant use disorder, a high proportion that reflects both the drug’s neurological impact and the difficulty of moderate or controlled use once a pattern of regular use is established.
Treatment Admissions: SAMHSA TEDS Data
The Treatment Episode Data Set (TEDS), published annually by SAMHSA, tracks substance use treatment admissions at facilities licensed or certified by state agencies across the country. The 2022 TEDS report, the most recently published at time of writing, analyzed nearly 1.5 million treatment admissions.
Methamphetamine was the primary substance of treatment concern in 13.9 percent of all admissions in 2022, accounting for approximately 171,882 episodes. This made methamphetamine the third most common primary substance cited in treatment admissions nationally, behind alcohol (35.5 percent) and heroin (16.9 percent), and ahead of other opioids and marijuana. The rate of methamphetamine-related treatment admissions was 62 per 100,000 population, per SAMHSA’s TEDS 2022 report.
Treatment admissions for methamphetamine were highest among individuals aged 21 to 44, the primary working-age population, and the demographic profile of admissions has diversified significantly over the past decade, with methamphetamine use disorder affecting growing proportions of women, older adults, and populations outside the western United States where the drug has historically been concentrated.
Overdose Mortality: The Lethal Cost of the Stimulant Crisis
Methamphetamine’s contribution to the national overdose crisis has grown sharply over the past decade and is a major part of the current drug crisis. According to NIDA’s drug overdose death statistics (sourced from CDC WONDER mortality data), deaths involving psychostimulants with abuse potential, primarily methamphetamine, rose from 5,716 in 2015 to 34,855 in 2023. This represents a more than sixfold increase in less than a decade.
According to the CDC’s overdose prevention data, in 2023, nearly 35,000 overdose deaths involved psychostimulants with abuse potential, approximately 33 percent of all overdose deaths that year. Approximately 70 percent of stimulant-involved overdose deaths in 2023 also involved illegally manufactured fentanyl (IMF), which shows how the stimulant crisis and the opioid crisis overlap. Many of these deaths involve people who may be using methamphetamine and are unknowingly exposed to fentanyl in the drug supply.
The most recent available CDC data, the NCHS Data Brief on drug overdose deaths 2023–2024, shows that between 2023 and 2024, the age-adjusted rate of deaths involving psychostimulants declined along with the overall overdose death rate, which fell 26.2 percent from 2023 to 2024 (the largest single-year decline in the 2014–2024 period). This is a meaningful development, though stimulant-involved deaths remain at historically elevated levels.
Demographic and Racial/Ethnic Disparities
Methamphetamine-related harms are not distributed evenly across the U.S. population. Federal data consistently show significant disparities by race, ethnicity, geography, and socioeconomic status.
CDC data on stimulant-involved overdose deaths, published in MMWR (Drug Overdose Deaths Involving Stimulants, 2018–2023), show that between 2018 and 2023, non-Hispanic American Indian and Alaska Native (AI/AN) people experienced the largest increases in psychostimulant-involved overdose death rates of any racial or ethnic group, with rates rising from 11.0 to 32.9 deaths per 100,000. These rates far exceed the national average and reflect disproportionate burden in communities already facing significant structural disadvantages.
The SAMHSA TEDS 2022 data also show that American Indian or Alaska Native individuals had the highest rate of treatment admissions of any racial/ethnic group at 1,766 per 100,000 population, more than eleven times the national rate of 62 per 100,000 for methamphetamine-specific admissions. These disparities reflect compounding effects of geographic availability, historical trauma, poverty, and inadequate access to prevention and treatment services.
Geographic Trends: From a Western Drug to a National Crisis
Historically, methamphetamine use was concentrated in western and rural states, particularly the Pacific Coast, Mountain West, and Midwest. That geographic pattern has shifted substantially. Federal data and research now document the expansion of methamphetamine use across the South, Midwest, and increasingly the Northeast, driven by the drug’s low cost and wide availability from large-scale distribution networks.
The PMC epidemiological review of methamphetamine in the United States documents that increases in methamphetamine use disorder were observed across multiple racial, ethnic, and geographic groups simultaneously, not just in historically high-prevalence areas. This nationalization of the meth crisis has significant implications for treatment infrastructure, as many eastern states and communities are less equipped with specialized stimulant treatment resources than western counterparts with longer institutional experience.
State-level NSDUH data from SAMHSA’s state releases confirm substantial variation in methamphetamine use rates across states, with several western states continuing to show the highest prevalence. However, the trend lines in many traditionally lower-prevalence states are rising. This is now a national rather than regional public health priority.
The Treatment Gap: Most People with Meth Use Disorder Are Not in Treatment
One of the most concerning aspects of the national methamphetamine statistics is the size of the treatment gap: the difference between the number of people who need treatment and those who actually receive it. Comparing the estimated 1.6 million people with past-year methamphetamine use disorder in 2022 (from NSDUH) to the approximately 171,882 methamphetamine-primary treatment admissions in TEDS 2022 suggests that the vast majority of people with this condition are not engaged in formal treatment.
Multiple factors contribute to this gap: stigma associated with stimulant use disorder, lack of awareness that effective treatment exists, geographic barriers to care (particularly in rural areas), the absence of FDA-approved medications for methamphetamine use disorder (unlike opioid use disorder, which has three approved pharmacotherapies), cost, insurance coverage gaps, and individual-level factors including denial, ambivalence about recovery, and untreated co-occurring mental health conditions.
Expanding access to evidence-based behavioral treatments, particularly contingency management and cognitive behavioral therapy (CBT), both of which have a strong evidence base for methamphetamine use disorder per NIDA, remains a central priority for clinicians, policymakers, and public health advocates working on this issue.
Professional Perspective
The numbers in this article tell a story that statistics alone can’t fully convey: a national crisis that has plateaued at historically elevated levels, a treatment gap counted in the millions, and a population disproportionately bearing the brunt, particularly American Indian and Alaska Native communities, where overdose rates run more than three times the national average. The crisis has spread well beyond the western states where meth use was once concentrated, and it now intersects directly with the opioid epidemic, with most stimulant overdose deaths now also involving fentanyl. SAMHSA’s Treatment Improvement Protocol on stimulant use disorders puts the treatment-side reality of all this in plain terms:
In plain terms: the tools to help people with methamphetamine use disorder exist, contingency management and cognitive behavioral therapy both have strong evidence behind them, but access to providers trained in those approaches lags well behind the scale of the crisis. For families and individuals trying to find help, that gap is real, and it’s why specialty programs with a track record in stimulant care matter.
What This Means When Looking for Treatment
The provider gap is real, but it doesn’t mean effective help is out of reach; it means knowing what to look for makes a real difference. The two treatments with the strongest evidence for methamphetamine use disorder are contingency management (a structured incentive-based approach that consistently shows the best outcomes for stimulant use) and cognitive behavioral therapy. When evaluating a treatment program, it’s worth asking directly whether they offer these approaches and what staff training looks like, rather than assuming any program that treats addiction handles meth the same way.
It’s also worth knowing that there are no FDA-approved medications for methamphetamine use disorder, unlike opioid use disorder, which has three. That makes the behavioral side of treatment, plus support for any co-occurring mental health conditions and a real plan for long-term recovery support, the foundation of effective care. Recovery from methamphetamine use disorder is possible, but the quality of the program matters more here than for almost any other substance.
Data-Driven Awareness, Compassionate Response
The statistics presented in this article reflect both the severity and the scope of methamphetamine use disorder in the United States. Millions of Americans are affected. The overdose toll continues to rise. The treatment gap remains vast. And yet recovery happens every day for people who access effective care.
These numbers should drive action to ensure that prevention, treatment, and harm reduction resources reach the people and communities that need them most. Federal data from SAMHSA, NIDA, and the CDC provide the foundation for making evidence-based decisions at every level, from individual clinical care to national policy.


